Bicara Therapeutics BCAX Effective Income Tax Rate Reconciliation Tax Credits Research
Effective Income Tax Rate Reconciliation Tax Credits Research at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch.
The official record: Bicara Therapeutics’s 10-K, filed March 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's effective income tax rate reconciliation tax credits research.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's effective income tax rate reconciliation tax credits research?
- Bicara Therapeutics (BCAX) reported effective income tax rate reconciliation tax credits research of -2.5% in Q4 2025.
- What does effective income tax rate reconciliation tax credits research mean?
- This metric quantifies the percentage impact of research and development tax credits on the company's overall effective tax rate. It reflects the company's ability to leverage government incentives to offset tax liabilities through innovation-related activities. A higher value indicates a more significant reliance on or success in utilizing R&D tax incentives.